Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 3/2021

11.08.2021 | review

Chronic lymphocytic leukaemia—what is new and notable in 2021, with a special focus on COVID-19

verfasst von: Katharina T. Prochazka, Peter Neumeister

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Summary

In the last few years, treatment of patients exhibiting chronic lymphocytic leukaemia has changed extensively due to advances in the development of targeted therapies. The role of immunochemotherapy has been for the most part replace and the guidelines have been modified accordingly. Herein, we give an overview on updated onkopedia guidelines, studded with updates of the landmark studies of the latest American Society of Hematology (ASH) meeting. In addition, since still crucial, recommendations concerning coronavirus disease 2019 (COVID-19) in chronic lymphocytic leukaemia patients will be covered.
Literatur
2.
Zurück zum Zitat Shanafelt T, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432–43.CrossRef Shanafelt T, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432–43.CrossRef
3.
Zurück zum Zitat Woyach J, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–28.CrossRef Woyach J, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–28.CrossRef
4.
Zurück zum Zitat Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278–91.CrossRef Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278–91.CrossRef
5.
Zurück zum Zitat Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–36.CrossRef Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–36.CrossRef
6.
Zurück zum Zitat Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208–15.CrossRef Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208–15.CrossRef
7.
Zurück zum Zitat Eichhorst B, Fink AM, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928–42.CrossRef Eichhorst B, Fink AM, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928–42.CrossRef
8.
Zurück zum Zitat Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–10.CrossRef Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–10.CrossRef
9.
Zurück zum Zitat Allan JN, Shanafelt T, Wiestner A, et al. Long-term efficacy of 1st-line ibrutinib for CLL with 4 years of FU in patients with TP53 aberrations: a pooled analysis from 4 clinical. Blood. 2020;136(Supplement 1):2219.CrossRef Allan JN, Shanafelt T, Wiestner A, et al. Long-term efficacy of 1st-line ibrutinib for CLL with 4 years of FU in patients with TP53 aberrations: a pooled analysis from 4 clinical. Blood. 2020;136(Supplement 1):2219.CrossRef
10.
Zurück zum Zitat Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107–20.CrossRef Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107–20.CrossRef
11.
Zurück zum Zitat Kater A, Kipps TJ, Eichhorst B, et al. 5‑year analysis of Murano study demonstrates enduring uMRD in a subset of R/R CLL patients following fixed-duration VenR. Blood. 2020;136(Supplement 1):19–21.CrossRef Kater A, Kipps TJ, Eichhorst B, et al. 5‑year analysis of Murano study demonstrates enduring uMRD in a subset of R/R CLL patients following fixed-duration VenR. Blood. 2020;136(Supplement 1):19–21.CrossRef
12.
Zurück zum Zitat Hallek M. The broadening landscape of targets and therapeutic options for CLL. In: EBMT handbook. 2021. Hallek M. The broadening landscape of targets and therapeutic options for CLL. In: EBMT handbook. 2021.
13.
Zurück zum Zitat Munir T, Brown JR, O’Brien S, et al. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94:1353–63.CrossRef Munir T, Brown JR, O’Brien S, et al. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94:1353–63.CrossRef
14.
Zurück zum Zitat Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (HELIOS): A randomized, double-blind, phase 3 study. Lancet Oncol. 2016;17:200–11.CrossRef Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (HELIOS): A randomized, double-blind, phase 3 study. Lancet Oncol. 2016;17:200–11.CrossRef
15.
Zurück zum Zitat Ghia P, Pluta A, Wach M, et al. ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38:2849–61.CrossRef Ghia P, Pluta A, Wach M, et al. ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38:2849–61.CrossRef
17.
Zurück zum Zitat Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–92.CrossRef Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–92.CrossRef
18.
Zurück zum Zitat Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patient. Blood. 2020;135(21):1912–5.CrossRef Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patient. Blood. 2020;135(21):1912–5.CrossRef
20.
Zurück zum Zitat Roeker LE, Knorr DA, Pessin MS, et al. Anti-SARS-CoV‑2 antibody response in patients with chronic lymphocytic leukemia. Leukemia. 2020;34:3047–9.CrossRef Roeker LE, Knorr DA, Pessin MS, et al. Anti-SARS-CoV‑2 antibody response in patients with chronic lymphocytic leukemia. Leukemia. 2020;34:3047–9.CrossRef
Metadaten
Titel
Chronic lymphocytic leukaemia—what is new and notable in 2021, with a special focus on COVID-19
verfasst von
Katharina T. Prochazka
Peter Neumeister
Publikationsdatum
11.08.2021
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00735-z

Weitere Artikel der Ausgabe 3/2021

memo - Magazine of European Medical Oncology 3/2021 Zur Ausgabe